Payment overview · 2025
General Payments
$156.99
6 reported records · 6 companies
Healthcare provider profile · identity verified
Jody A. Stark, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · ONTARIO, OR · NPI 1851472989
Verified facts
What the public records show
CMS Open Payments records show Jody A. Stark, NP received $156.99 in general payments during 2025 across 6 reported records.
Novo Nordisk Inc accounted for 49.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Rybelsus by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $77.45 | 49.3% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $19.04 | 12.1% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $16.00 | 10.2% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $15.61 | 9.9% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $14.88 | 9.5% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $14.01 | 8.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $156.99 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $77.45 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $19.04 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $16.00 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $15.61 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $14.88 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $14.01 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
88 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 572 | 85 |
| Levothyroxine Sodium | Levothyroxine Sodium | 546 | 129 |
| Losartan Potassium | Losartan Potassium | 448 | 115 |
| Omeprazole | Omeprazole | 334 | 94 |
| Atorvastatin Calcium | Atorvastatin Calcium | 306 | 78 |
| Amlodipine Besylate | Amlodipine Besylate | 293 | 73 |
| Metoprolol Succinate | Metoprolol Succinate | 219 | 60 |
| Potassium Chloride | Potassium Chloride | 199 | 57 |
| Metformin Hcl | Metformin Hcl | 194 | 44 |
| Gabapentin | Gabapentin | 190 | 35 |
| Sertraline Hcl | Sertraline Hcl | 177 | 48 |
| Furosemide | Furosemide | 173 | 45 |
| Lorazepam | Lorazepam | 163 | 32 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 148 | 28 |
| Lisinopril | Lisinopril | 146 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 139 | 35 |
| Tramadol Hcl | Tramadol Hcl | 133 | 34 |
| Duloxetine Hcl | Duloxetine Hcl | 132 | 30 |
| Montelukast Sodium | Montelukast Sodium | 132 | 32 |
| Mounjaro | Tirzepatide | 127 | 15 |
| Buspirone Hcl | Buspirone Hcl | 121 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 111 | 38 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 110 | 28 |
| Pregabalin | Pregabalin | 107 | 23 |
| Alprazolam | Alprazolam | 102 | 17 |
| Azithromycin | Azithromycin | 98 | 61 |
| Fluconazole | Fluconazole | 98 | 40 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 94 | 58 |
| Eliquis | Apixaban | 92 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 90 | 18 |
| Ozempic | Semaglutide | 88 | 19 |
| Trulicity | Dulaglutide | 85 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 83 | 19 |
| Trazodone Hcl | Trazodone Hcl | 81 | 21 |
| Alendronate Sodium | Alendronate Sodium | 79 | 19 |
| Oxycodone Hcl | Oxycodone Hcl | 77 | suppressed |
| Cephalexin | Cephalexin | 76 | 53 |
| Prednisone | Prednisone | 76 | 37 |
| Allopurinol | Allopurinol | 74 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 74 | 20 |
| Clonazepam | Clonazepam | 72 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 71 | 22 |
| Estradiol | Estradiol | 62 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 62 | 23 |
| Celecoxib | Celecoxib | 60 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 60 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 59 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 59 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 58 | 21 |
| Meloxicam | Meloxicam | 58 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 56 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 56 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 53 | 38 |
| Tizanidine Hcl | Tizanidine Hcl | 53 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 51 | 17 |
| Ventolin Hfa | Albuterol Sulfate | 51 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 50 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 49 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 48 | suppressed |
| Levofloxacin | Levofloxacin | 48 | 33 |
| Warfarin Sodium | Warfarin Sodium | 47 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 46 | suppressed |
| Novolog Flexpen | Insulin Aspart | 46 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 46 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 46 | 22 |
| Glimepiride | Glimepiride | 45 | suppressed |
| Olanzapine | Olanzapine | 45 | suppressed |
| Simvastatin | Simvastatin | 45 | 13 |
| Ibuprofen | Ibuprofen | 44 | 18 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 43 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 42 | suppressed |
| Spironolactone | Spironolactone | 41 | 13 |
| Rizatriptan | Rizatriptan Benzoate | 40 | suppressed |
| Acyclovir | Acyclovir | 38 | 16 |
| Clonidine Hcl | Clonidine Hcl | 38 | suppressed |
| Ezetimibe | Ezetimibe | 38 | 12 |
| Risperidone | Risperidone | 37 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 37 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 35 | 12 |
| Lovastatin | Lovastatin | 34 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 33 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 32 | suppressed |
| Rybelsus | Semaglutide | 32 | suppressed |
| Atenolol | Atenolol | 31 | suppressed |
| Bupropion Xl | Bupropion Hcl | 31 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 31 | suppressed |
| Temazepam | Temazepam | 30 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 30 | suppressed |
| Aripiprazole | Aripiprazole | 29 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Carvedilol | Carvedilol | 28 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 27 | 22 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 24 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 24 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 23 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 23 | suppressed |
| Famotidine | Famotidine | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 23 | suppressed |
| Linzess | Linaclotide | 22 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 19 | suppressed |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 19 | suppressed |
| Amoxicillin | Amoxicillin | 17 | 13 |
| Finasteride | Finasteride | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 17 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 17 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 17 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Lidocaine | Lidocaine | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Vraylar | Cariprazine Hcl | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Fentanyl | Fentanyl | 14 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Butorphanol Tartrate | Butorphanol Tartrate | 13 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Edarbi | Azilsartan Medoxomil | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Efavirenz-Emtric-Tenofov Disop | Efavirenz/Emtricit/Tenofovr Df | 12 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Mesalamine Dr | Mesalamine | 12 | suppressed |
| Methadone Hcl | Methadone Hcl | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Pentoxifylline | Pentoxifylline | 12 | suppressed |
| Ssd | Silver Sulfadiazine | 12 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
| Zaleplon | Zaleplon | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $156.99 · 6 records | Novo Nordisk Inc | CAPLYTA, JOURNAVX, REXULTI, TZIELD, Wegovy, YUPELRI | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error